Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q3 FY22 results · Oct–Dec 2021
Dr. Lal Path Labs reported revenue from operations of ₹496.90 crore (up 9.8% from Q3 FY21) and net profit of ₹58.20 crore (down 39.3% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 496.90 | 452.40 | +9.8% | 498.40 | −0.3% |
| Other income | 12.10 | 13.50 | −10.4% | 14.30 | −15.4% |
| Total income | 509.00 | 465.90 | +9.3% | 512.70 | −0.7% |
| Profit before tax | 81.50 | 128.90 | −36.8% | 130.60 | −37.6% |
| Net profit for the period | 58.20 | 95.90 | −39.3% | 96.30 | −39.6% |
| Attributable to shareholders of the company | 57.30 | 94.50 | −39.4% | 95.00 | −39.7% |
| EPS, basic (₹) | 6.93 | 11.44 | −39.4% | 11.49 | −39.7% |
| Net margin (%) | 11.7 | 21.2 | 19.3 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 422.50 | 427.10 | −1.1% | 470.40 | −10.2% |
| Other income | 11.30 | 14.60 | −22.6% | 15.30 | −26.1% |
| Total income | 433.80 | 441.70 | −1.8% | 485.70 | −10.7% |
| Profit before tax | 83.20 | 124.10 | −33.0% | 125.90 | −33.9% |
| Net profit for the period | 61.70 | 92.70 | −33.4% | 93.90 | −34.3% |
| EPS, basic (₹) | 7.46 | 11.23 | −33.6% | 11.36 | −34.3% |
| Net margin (%) | 14.6 | 21.7 | 20.0 |
Consolidated
- Filed with BSE
- 10 Feb 2022, 18:06 IST
- Board meeting
- 10 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Feb 2022, 18:06 IST
- Board meeting
- 10 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE